Clonal hypereosinophilic conditions: Chronic eosinophilic leukemia (CEL) + L-HES
Clonal hypereosinophilic conditions: Chronic eosinophilic leukemia (CEL) + L-HES
Speakers: Massimo Breccia, Florence Roufosse
Prof. Massimo Breccia is an associate Professor at Sapienza University of Rome, Azienda Policlinico Umberto I, head of DH unit and of myeloid disorders group. His scientific interests and publications as author or co-author (more than 500 papers in peer reviewed journals) are mainly focused on biological and clinical aspects of acute and chronic myeloid leukemias and myelodysplastic syndromes. He is the editor in chief of Annals of Hematology journal, associate editor of Cancer Medicine, Frontiers in Oncology, Cancers, and a peer-reviewer for several journals such as Blood, The Lancet, The Lancet Hematology, Haematologica, British Journal of Haematology, Cancer, etc and member of editorial board or associate editor of several other journals. He is a member of SIE, SIES, EHA and participates as PI and SI in several clinical trials (in particular phase 1) for CML, AML and MDS. He is co-chair of GIMEMA QoL Working Party and elected member of MPN GIMEMA Working Party.
Dr. Florence Roufosse is Professor of Medicine, Internist and Clinical Immunologist at HUB-Hôpital Erasme, Brussels, and is Past President of the International Eosinophil Society. She is in charge of a specialized consultation dedicated to diagnosing and treating eosinophil-related conditions, that is integrated in the European Reference Network: EuroBloodNet. She also manages patients with systemic auto-immune and auto-inflammatory conditions. Besides these clinical activities, Dr. Roufosse leads translational research projects to improve understanding and treatment of lymphocytic variant hypereosinophilic syndrome (HES), and participates in international research efforts to better delineate disease course and treatment responses in patients with HES. She is involved in the design and conduct of international clinical trials evaluating efficacy of novel treatment options for HES and eosinophilic granulomatosis with polyangiitis (EGPA), as well as sub-studies that aim to identify biomarkers and/or disease variants predicting treatment responses.